This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Upadhya, S. Articles by Pai, R. G. Search for Related Content PubMed PubMed Citation Articles by Upadhya, S. Articles by Pai, R. G. Social Bookmarking                         What's this?

Atherogenic Effect of Interleukin-2 and Antiatherogenic Effect of Interleukin-2 Antibody in Apo-E-Deficient Mice

Loma Linda University and VA Medical Centers, Loma Linda, CA

Shanthalaxmi Mooteri, MD

Loma Linda University and VA Medical Centers, Loma Linda, CA

Norman Peckham, MD

Loma Linda University and VA Medical Centers, Loma Linda, CA

Ramdas G. Pai, MD

Loma Linda University and VA Medical Centers, Loma Linda, CA, ramdaspai{at}yahoo.com

Growing evidence suggests that atherosclerosis is an immune-mediated inflammatory process and that cytokines participate as mediators in this process. Of the cytokines, interleukins, which are released from both immune and nonimmune cells of vascular wall, are found to have multiple effects. Interleukin-2 (IL-2), a cytokine produced by activated T-lymphocytes, has been found to further activate the T cells and may potentially enhance atherogenesis. Apo-E-deficient mice fed with atherogenic diet were injected intraperitoneally twice a week with placebo, IL-2, or anti-IL-2 antibody for a period of 6 weeks. Group 1 (n=6) was injected with bovine serum albumin (BSA) in phosphate-buffered saline (PBS) and served as controls. Group 2 (n=6) was injected with 2x10⁴ units of recombinant murine IL-2 (rmIL-2) per dose reconstituted with BSA in PBS. Group 3 (n=6) was injected with 5 µg of anti-IL-2 per dose reconstituted with BSA in PBS. Aortic sections were analyzed and atherosclerotic burden was quantified. Compared to controls, injection of IL-2 increased measures of atherosclerosis such as the average lesion score (10.7 ±0.5 vs 9.3 ±1.1, p=0.04) and the lesion size as a fraction of aortic area (0.51 ±0.03 vs 0.41 ±0.05, p=0.01). Injection of anti-IL-2 had a profound antiatherogenic effect. It significantly reduced the average number of lesions per cross section (2.6 ±0.6 vs 4.3 ±0.6, p=0.03), the average lesion score (4.6 ±1.9 vs 9.3 ±1.1, p=0.02), the lesion area/circumference (0.35 ±0.08 vs 0.62 ±0.10, p=0.007), and the lesion size/aortic area (0.23 ±0.07 vs 0.41 ±0.05, p=0.03). These results indicate that IL-2 is an atherogenic cytokine in apo-E-deficient mice and anti-IL-2 is protective against atherosclerosis. This may have important clinical implications in modifying the atherosclerotic process.

Angiology, Vol. 55, No. 3, 289-294 (2004)
DOI: 10.1177/000331970405500308


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. Kleemann, S. Zadelaar, and T. Kooistra Cytokines and atherosclerosis: a comprehensive review of studies in mice Cardiovasc Res, August 1, 2008; 79(3): 360 - 376. [Abstract] [Full Text] [PDF]

				E. Dyroy, T. H. Rost, R. J. Pettersen, B. Halvorsen, O. A. Gudbrandsen, T. Ueland, Z. Muna, F. Muller, J. E. Nordrehaug, P. Aukrust, et al. Tetradecylselenoacetic Acid, a PPAR Ligand With Antioxidant, Antiinflammatory, and Hypolipidemic Properties Arterioscler Thromb Vasc Biol, March 1, 2007; 27(3): 628 - 634. [Abstract] [Full Text] [PDF]

				A. Tedgui and Z. Mallat Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways Physiol Rev, April 1, 2006; 86(2): 515 - 581. [Abstract] [Full Text] [PDF]

				S G Baidya and Q-T Zeng Helper T cells and atherosclerosis: the cytokine web Postgrad. Med. J., December 1, 2005; 81(962): 746 - 752. [Abstract] [Full Text] [PDF]

				J. Ge, Q. Jia, C. Liang, Y. Luo, D. Huang, A. Sun, K. Wang, Y. Zou, and H. Chen Advanced Glycosylation End Products Might Promote Atherosclerosis Through Inducing the Immune Maturation of Dendritic Cells Arterioscler Thromb Vasc Biol, October 1, 2005; 25(10): 2157 - 2163. [Abstract] [Full Text] [PDF]